Loading...
Loading...
- Cabaletta Bio Inc CABA has announced 28-day clinical data from the third dose cohort (500 million DSG3-CAART cells) in the DesCAARTes Phase 1 trial for mucosal-dominant pemphigus vulgaris (mPV).
- The Company observed a dose-dependent increase in DSG3-CAART persistence in the third cohort relative to the first two low dose cohorts throughout the 28 days following infusion.
- In addition, no clinically relevant adverse events (DLTs) were observed.
- These safety data were observed without preconditioning and in the presence of circulating anti-DSG3 antibodies.
- Dosing of patients in the fourth cohort at a treatment dose of 2.5 billion DSG3-CAART cells has been initiated.
- 28-day safety data from the fourth dose cohort is expected in the Q1 of 2022.
- Top-line biologic activity data for the first two low-dose cohorts will be announced in Q4 of 2021.
- Related Link: Cabaletta Bio's Cell Therapy Shows Encouraging Safety Profile In Autoimmune Skin Disorder.
- Cabaletta ended Q3 with $119.3 million in cash, extending the cash runway to fund operations through at least 1Q23.
- Price Action: CABA shares closed higher by 4.12% at $14.37 on mONDAY.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in